Innovative nanotechnologies for the delivery of oligonucleotides and siRNA.
One way to reach intracellular therapeutic targets in cells consists in the use of short nucleic acids which will bind specifically to on targets thanks to either Watson-Crick base pairing or protein nucleic acids recognition rules. Among these short nucleic acids an important class of therapeutic agents is antisense oligonucleotides and siRNAs. However, the major problem of nucleic acids is their poor stability in biological media. One method, among others, to solve the stability problem is the use of colloïdal carriers such as nanoparticles. Nanoparticles have already been applied with success to in vitro drug delivery to particular types of cells and in vivo in several experimental models. Many membrane and intracellular processes deal with nanosized structure (typically 100 nm) which are processed further through the recognition sites of receptors and enzymes. Thus non-viral nanoparticles are interesting candidates to present biochemical molecules such as nucleic acids and proteins to cells as well as to protect them in vivo during delivery. This review focuses on the recent developments in the design of nanotechnologies to improve the delivery of antisense oligonucleotides and siRNAs.
Toub
N
N
Laboratoire de Physicochimie, Pharmacotechnie et Biopharmacie, UMR CNRS 8612, Faculté de Pharmacie, 5, rue Jean-Baptiste-Clement, 92286 Châtenay-Malabry cedex, France.
Malvy
C
C
Fattal
E
E
Couvreur
P
P
D000818:Animals; D004337:Drug Carriers; D006801:Humans; D036103:Nanotechnology; D016376:Oligonucleotides, Antisense / Q000008:administration & dosage*; D034741:RNA, Small Interfering / Q000008:administration & dosage*
D004337:Drug Carriers; D016376:Oligonucleotides, Antisense; D034741:RNA, Small Interfering